In this instance, the risk allele encourages exon 6 skipping with the development of a new soluble version of the tumor necrosis factor (TNF) receptor that may limit TNF signaling within cells, somewhat resembling the effects exacerbating TNF-blocking medications during MS [82]. The gene discussed is TNF; the disease is myeloid sarcoma.